Irsogladine maleate

Cat. No.: HY-B0327A
CAS No.: 84504-69-8
Molecular Formula: C₁₃H₁₁Cl₂N₅O₄
Molecular Weight: 372.16
Target: mAChR; Phosphodiesterase (PDE)
Pathway: GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease
Storage: Please store the product under the recommended conditions in the COA.

BIOLOGICAL ACTIVITY

Description
Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. Target: PDE4; mACHRIrsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. Irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898       Fax: 609-228-5909       E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA